Hollander P, et al. - The safety and efficacy of ertugliflozin (an oral sodium-glucose cotransporter 2 inhibitor) vs glimepiride were assessed in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin. In reducing HbA1c, ertugliflozin 15 mg was non-inferior to glimepiride when added to metformin in patients with T2DM. Ertugliflozin had an acceptable safety profile. Compared to glimepiride, ertugliflozin resulted in less hypoglycemia and more genital mycotic infections (GMIs).